Integrated functional, gene expression and genomic analysis for the identification of cancer targets.
The majority of new drug approvals for cancer are based on existing therapeutic targets. One approach to the identification of novel targets is to perform high-throughput RNA interference (RNAi) cellular viability screens. We describe a novel approach combining RNAi screening in multiple cell lines...
Guardado en:
Autores principales: | Elizabeth Iorns, Christopher J Lord, Anita Grigoriadis, Sarah McDonald, Kerry Fenwick, Alan Mackay, Charles A Mein, Rachael Natrajan, Kay Savage, Narinder Tamber, Jorge S Reis-Filho, Nicholas C Turner, Alan Ashworth |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe6d4e18e3ac4117937a53debf5472d2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
NLK is a novel therapeutic target for PTEN deficient tumour cells.
por: Ana M Mendes-Pereira, et al.
Publicado: (2012) -
Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer.
por: Louise J Barber, et al.
Publicado: (2011) -
A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
por: Stephen J Pettitt, et al.
Publicado: (2013) -
A modified method for whole exome resequencing from minimal amounts of starting DNA.
por: Iwanka Kozarewa, et al.
Publicado: (2012) -
Africa's 32 cents solution for HIV/AIDS.
por: Peter J Hotez, et al.
Publicado: (2009)